July 21, 2008
Uroplasty Joins National Association For Continence’s Industry Council
MINNEAPOLIS, July 21 /PRNewswire-FirstCall/ -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, today announced that it has become a member of the National Association For Continence's (NAFC) Industry Council.
"Uroplasty looks forward to contributing in a meaningful way to the important public programming and advocacy that NAFC brings to the very large community impacted by incontinence issues," said Uroplasty's President and Chief Executive Officer, David Kaysen. "NAFC is an important resource for those seeking solutions to incontinence and a voice for a meaningful public health debate around this problem; we plan to leverage our unique expertise to help this important organization continue its valuable work."
Uroplasty joins a team of thirteen other pharmaceutical, device, and medical products companies which support NAFC's programs in public health education, communications and collaboration with professional societies, and advocacy.
An estimated 33 million people in the United States suffer from an overactive bladder and an estimated 12.2 million of these adults have urge incontinence.(1) Although overactive bladder is most common among older adults and women, it does not discriminate. In fact, starting at age 60, men who report symptoms of overactive bladder begin to outnumber women who do so, with about 42% of men over age 74 reporting symptoms compared with 32% of women in the same age group.(2) Anyone, at any age, can suffer from the symptoms of this problem.
Uroplasty offers a pioneering procedure called the Urgent(R) PC Neuromodulation System, which is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms. Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.
For more information about the Urgent(R) PC Neuromodulation System, please call 866-277-0466 or visit http://www.uroplasty.com/.
About the National Association For Continence (NAFC)
The National Association For Continence is a 501(c)3 corporation whose mission is threefold: 1) to educate the public about the causes, diagnosis categories, treatment options, and management alternatives for incontinence, voiding dysfunction, nocturnal enuresis, and related pelvic floor disorders; 2) to network with other organizations and agencies to elevate the visibility and priority given to these areas; and 3) to advocate on behalf of consumers who suffer from such symptoms as a result of disease or other illness, obstetrical, surgical or other trauma, or deterioration due to the aging process itself. NAFC is broadly funded by consumers, healthcare professionals and industry. It is the world's largest and most prolific consumer advocacy organization devoted exclusively to this field. Visit http://www.nafc.org/ to learn more.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with a diagnosis of overactive bladder (OAB). We also offer Macroplastique(R) Implants, an injectable, minimally invasive urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://www.uroplasty.com/.
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, 952.426.6140 EVC Group Doug Sherk/Dahlia Bailey (Investors) 415.896.6820 Chris Gale (Media) 646.201.5431 (1) Stewart WR et al. Prevalence and impact of OAB in the US: results from the NOBLE program. Neurological Urodynamics. 2001; 20:406-408. (2) Muller N. What Americans Understand How they Affected by Bladder Control Problems: Highlights of Recent Nationwide Consumer Research. Urologic Nursing. 2005:25(2): 109-115.
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, VicePresident, CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; orinvestors, Doug Sherk or Dahlia Bailey, +1-415-896-6820, or media, Chris Gale,+1-646-201-5431, all of EVC Group, for Uroplasty, Inc.
Web site: http://www.uroplasty.com/